Amarin Corporation Plc (AMRN)
| Market Cap | 2.13B |
| Revenue (ttm) | 620.41M |
| Net Income (ttm) | 4.32M |
| Shares Out | 395.30M |
| EPS (ttm) | 0.01 |
| PE Ratio | 540.00 |
| Forward PE | 500.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,763,392 |
| Open | 5.40 |
| Previous Close | 5.44 |
| Day's Range | 5.33 - 5.52 |
| 52-Week Range | 3.58 - 9.25 |
| Beta | 2.24 |
| Analysts | Buy |
| Price Target | 10.75 (+99.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About AMRN
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commerciali...
Financial Performance
In 2020, Amarin's revenue was $614.06 million, an increase of 42.89% compared to the previous year's $429.76 million. Losses were -$18.00 million, -20.51% less than in 2019.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for Amarin stock is "Buy." The 12-month stock price forecast is 10.75, which is an increase of 99.07% from the latest price.
News
Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.
Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and Reimbursement Enables Amarin to Drive Additional Demand, Improve Patient Access & Educatio...
Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany
Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategy Brings groundbreaking therapy to patients in Germany with resi...
Amarin to Participate in September Investment Conferences
DUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that members of the senior leadership team will participate in two upcoming...
7 Busted Biotech Stocks Due for a Rebound
Buying biotech stocks while they're down is rewarding once they post positive clinical results, setting the stage for a big rally. The post 7 Busted Biotech Stocks Due for a Rebound appeared first on In...
5 Stocks With 195% to 467% Upside, According to Wall Street
If these high-water price targets come to fruition, investors will be all smiles.
Amarin Reports Overview of Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) and Eicosapentaenoi...
VASCEPA/VAZKEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in REDUCE-IT patients with prior Myocardial Infarction
Amarin Stock Moves Higher As Vascepa Cuts Risk Of Heart Attacks
Amarin Corporation plc (NASDAQ: AMRN) announced additional data on Vascepa/Vazkepa (icosapent ethyl) in patients with prior heart attack, known as myocardial infarction (MI), at risk for major adverse c...
Amarin Reports Data from REDUCE-IT® Showing VASCEPA®/VAZKEPA (Icosapent Ethyl) Significantly Reduces Ischemic Events ...
VASCEPA found in prespecified and post hoc analyses to reduce first and total primary endpoints by 26% and 35%, respectively, in patients with prior Myocardial Infarction
Latest Clinical Research Evaluating VASCEPA®/VAZKEPA (Icosapent Ethyl) in Patients with Residual Cardiovascular Risk ...
Amarin-Supported Research and Analyses from International Academic Collaborators to Be Featured in Seven Presentations Amarin-Supported Research and Analyses from International Academic Collaborators to...
Amarin (AMRN) Q2 Earnings Top, Vascepa Strong Despite Generics
Amarin's (AMRN) Vascepa sales benefit from increased demand in the United States during the second quarter. The drug retains majority market share in its segment amid rising generic competition.
Why Amarin Is Soaring Today
The pharmaceuticals company is showing surprising resilience in the face of competition.
Recap: Amarin Q2 Earnings
Shares of Amarin Corp (NASDAQ:AMRN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 100.00% over the past year to $0.02, which beat th...
Amarin Reports Second Quarter and Six Month 2021 Financial Results and Provides Business Update
Commercial Launch of VAZKEPA in Europe on Track to Commence in September in Germany
Best Penny Stocks to Buy? 3 to Watch In the Second Half of 2021
Looking for penny stocks to watch in the second half of 2021? Check these 3 out The post Best Penny Stocks to Buy?
What's in the Cards for Amarin (AMRN) This Earnings Season?
Amarin's (AMRN) second-quarter results are likely to reflect recovery in Vascepa sales amid potential recovery in COVID-19 related disruptions.
7 Reddit Penny Stocks About to Explode
With Reddit's regular targets finally dropping, these stocks could be the next target for another crazy wave of Reddit Penny Stocks. The post 7 Reddit Penny Stocks About to Explode appeared first on Inv...
Amarin to Report Second Quarter and Six Month 2021 Financial Results and Host Conference Call on August 5, 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., July 15, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin senior management...
Why Amarin Fell Again Today
Another Vascepa generic is launched in the U.S.
Why Amarin Stock Is Sinking Today
The biotech's attempt to revive Vascepa's U.S. patent protection appears to be at a dead end.
7 Hot Penny Stocks to Watch That Are Trending Right Now
Which penny stocks are worth buying next month? Check these 7 out for your watchlist The post 7 Hot Penny Stocks to Watch That Are Trending Right Now appeared first on Penny Stocks to Buy, Picks, News a...
Further Insights into Mechanism of Action of Icosapent Ethyl and Its Unique Form of Eicosapentaenoic Acid (EPA) Prese...
Studies support potentially important anti-inflammatory, protein modulation, and cell function effects of icosapent ethyl as known by the brand name VASCEPA® in much of the world and as VAZKEPA in Europ...
Why Amarin Trounced the Market on Tuesday
Investors reacted positively to a company presentation at an industry convention.
Amarin to Present at Two Investor Conferences in June 2021
DUBLIN, Ireland and BRIDGEWATER, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, Amarin's president and chief executive officer, and Karim...
Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the...
REDUCE-IT® patients experienced substantial cardiovascular (CV) risk reduction with icosapent ethyl regardless of the presence or degree of dyslipidemia, as defined by various high TG plus low HDL-C levels